Primary vs. Secondary Hemostasis
Primary (platelet/vWF) = immediate mucocutaneous bleeding (epistaxis, petechiae, menorrhagia); Secondary (factors) = delayed deep bleeding (hemarthroses, muscle hematomas).
von Willebrand Disease (vWD)
Most common inherited bleeding disorder (AD); ↑ Bleeding Time + ↑ PTT (vWF stabilizes Factor VIII!), normal platelets/PT; Rx: Desmopressin (DDAVP).
TTP vs. HUS vs. DIC
TTP (ADAMTS13 deficiency, uncleaved vWF multimers) & HUS (Shiga toxin) have NORMAL PT/PTT & fibrinogen; DIC (TF activation) has ↑ PT, ↑ PTT, ↑ D-dimer, ↓ fibrinogen.
TTP Emergency Management
Pentad (MAHA schistocytes, thrombocytopenia, neurologic signs, renal injury, fever); Emergent Plasmapheresis (PEX); PLATELET TRANSFUSION IS CONTRAINDICATED!
Heparin-Induced Thrombocytopenia
IgG against PF4-heparin complex 5–10 days after exposure → > 50% platelet drop + arterial/venous THROMBOSIS; stop all heparin and start Argatroban or Bivalirudin.
Bernard-Soulier vs. Glanzmann
Bernard-Soulier = GpIb defect (adhesion: giant platelets, abnormal ristocetin); Glanzmann = GpIIb/IIIa defect (aggregation: normal size, normal ristocetin).
1:1 Plasma Mixing Study
Isolated prolonged PTT: Corrects = Factor VIII/IX/XI deficiency (Hemophilia); Fails to correct = Inhibitor (Lupus Anticoagulant [thrombosis!] or acquired Factor VIII antibody).
Inherited Thrombophilias
Factor V Leiden (#1) = mutated Factor V resistant to cleavage by Activated Protein C; Antithrombin deficiency = heparin resistance (PTT fails to rise with UFH).
Primary vs. Secondary Hemostasis Disorders
Hemostatic disorders are divided into Primary Hemostasis defects (qualitative or quantitative platelet disorders and von Willebrand disease, which present with immediate mucocutaneous bleeding: petechiae, purpura, epistaxis, gingival bleeding, and menorrhagia) and Secondary Hemostasis defects (coagulation factor deficiencies such as Hemophilia A and B, which present with delayed deep tissue bleeding: hemarthroses, intramuscular hematomas, and retroperitoneal hemorrhage). Integrating platelet count, Prothrombin Time (PT/INR), and Activated Partial Thromboplastin Time (aPTT) localizes the exact hemostatic defect.
Thrombotic Thrombocytopenic Purpura (TTP) due to ADAMTS13 deficiency presents with the classic FAT RN Pentad (TTP pentad: Fever, Anemia, Thrombocytopenia, Renal failure, Neurologic dysfunction).
| Bleeding Disorder | Pathophysiologic Mechanism | Platelet Count & Coagulation Studies | Distinguishing Clinical Hallmarks |
|---|---|---|---|
| Immune Thrombocytopenia (ITP) | Autoantibodies against platelet GPIIb/IIIa receptors -> splenic macrophage destruction | Isolated thrombocytopenia (< 100k); normal PT and PTT | Petechiae, purpura, epistaxis, menorrhagia; Corticosteroids (Prednisone), IVIG, or anti-D immune globulin |
| Thrombotic Thrombocytopenic Purpura (TTP) | Severe deficiency in ADAMTS13 metalloprotease -> ultra-large vWF multimers induce microthrombi | Thrombocytopenia, normal PT/PTT, schistocytes on blood smear, high LDH, low haptoglobin | FAT RN: Fever, Anemia, Thrombocytopenia, Renal, Neurologic; Emergent Plasma Exchange (PEX) |
| Disseminated Intravascular Coagulation (DIC) | Systemic activation of coagulation cascade consuming clotting factors and platelets (sepsis, trauma, malignancy, obstetric) | Low platelets, prolonged PT, prolonged PTT, low fibrinogen, dramatically elevated D-dimer | Oozing from venipuncture sites, cataclysmic bleeding + microvascular thrombosis; treat underlying sepsis/cause |
| Hemophilia A and B | X-linked recessive deficiency of Factor VIII (Hemophilia A) or Factor IX (Hemophilia B) | Normal platelets, normal PT, prolonged PTT (corrects with 1:1 mixing study) | Deep tissue bleeding: hemarthroses, muscle hematomas, post-surgical hemorrhage; recombinant factor replacement |
Thrombocytopenic Microangiopathies: ITP (Isolated Low Platelets) vs. TTP (ADAMTS13 Pentad) vs. HUS vs. DIC
When a patient presents with thrombocytopenia (<150,000/μL), the first step is to check the Peripheral Blood Smear (to rule out EDTA-induced platelet clumping pseudothrombocytopenia and look for schistocytes [helmet cells]) alongside the PT/INR and aPTT: (1) Immune Thrombocytopenia (ITP) (IgG autoantibodies against platelet GpIIb/IIIa cleared by splenic macrophages) presents with isolated mucocutaneous petechiae/epistaxis, isolated thrombocytopenia (often <20,000/μL), a normal peripheral smear (no schistocytes, large megakaryocytic platelets), and completely NORMAL PT and aPTT; in children, ITP follows a viral URI and resolves spontaneously in 80% of cases, whereas adults with platelets <30,000/μL or active bleeding receive Corticosteroids and/or IVIG (or Anti-D immune globulin if Rh+), with second-line Rituximab, Thrombopoietin receptor agonists (romiplostim, eltrombopag), or Splenectomy. (2) Thrombotic Thrombocytopenic Purpura (TTP) (congenital or acquired autoantibody deficiency of ADAMTS13, the metalloprotease that cleaves ultra-large von Willebrand Factor [vWF] multimers) causes massive platelet-rich microvascular thrombi that shear RBCs into schistocytes (Microangiopathic Hemolytic Anemia [MAHA]: high LDH, high indirect bilirubin, low haptoglobin), producing the classic Pentad (FAT RN): Fever, Anemia (MAHA), Thrombocytopenia, Renal insufficiency, and Neurological deficits (confusion, stroke, seizures)—critically, because only platelets are consumed without activating the coagulation cascade, PT and aPTT are NORMAL in TTP and HUS! Treat TTP immediately with emergent Plasmapheresis (Plasma Exchange, which removes anti-ADAMTS13 autoantibodies and replenishes fresh ADAMTS13) + Corticosteroids + Caplacizumab—NEVER transfuse platelets in TTP (or HIT!), as transfused platelets fuel microvascular thrombosis and stroke ('adding fuel to the fire')! (3) Typical Hemolytic Uremic Syndrome (HUS) occurs in children after bloody diarrhea from Shiga-toxin–producing E. coli O157:H7 (STEC) (inhibiting the 60S ribosome of glomerular endothelial cells), presenting with the triad of MAHA, Thrombocytopenia, and Acute Kidney Injury (with normal PT/aPTT); treat supportively (avoid antibiotics and antimotility agents in STEC, as they increase Shiga toxin release!). (4) Disseminated Intravascular Coagulation (DIC) (triggered by sepsis, trauma, obstetric abruption/amniotic fluid embolism, acute promyelocytic leukemia, or rattlesnake envenomation) consumes both platelets AND coagulation factors—uniquely producing LOW Platelets + Schistocytes + PROLONGED PT AND PROLONGED aPTT + LOW Fibrinogen + ELEVATED D-Dimer!
von Willebrand Disease (Desmopressin & Prolonged PTT), Hemophilia A/B, Qualitative Platelet Defects (Bernard-Soulier vs. Glanzmann) & HIT
Master four additional high-yield hemostasis conditions: (1) von Willebrand Disease (vWD) is the #1 inherited bleeding disorder (autosomal dominant Type 1 quantitative deficiency in 80% of cases): because vWF performs two jobs—mediating platelet adhesion to subendothelial collagen via GpIb AND serving as the protective carrier protein for Coagulation Factor VIII in plasma—vWD uniquely presents with mucocutaneous primary hemostatic bleeding (menorrhagia, epistaxis, post-dental oozing), a NORMAL platelet count, a prolonged Bleeding Time / abnormal Ristocetin Cofactor Assay, AND a NORMAL OR PROLONGED aPTT (due to accelerated Factor VIII degradation)! Treat Type 1 vWD and mild Hemophilia A with Desmopressin (DDAVP), which stimulates endothelial V2 receptors to release preformed vWF and Factor VIII from Weibel-Palade bodies (or vWF-Factor VIII concentrates for severe bleeding). (2) Hemophilia A (Factor VIII deficiency, X-linked recessive) and Hemophilia B (Factor IX deficiency [Christmas disease], X-linked recessive) present in boys with delayed deep hemarthroses, intramuscular hematomas, a NORMAL platelet count, NORMAL PT, and isolated PROLONGED aPTT that corrects on a 1:1 mixing study (if mixing fails to correct, the patient has an acquired Factor VIII inhibitor). (3) Qualitative Bernard-Soulier vs. Glanzmann Thrombasthenia: Bernard-Soulier Syndrome is a defect in platelet GpIb (adhesion to vWF), featuring GIANT platelets, mild thrombocytopenia, and an ABNORMAL Ristocetin aggregation test; Glanzmann Thrombasthenia is a defect in platelet GpIIb/IIIa (aggregation via fibrinogen bridges), featuring a normal platelet count/morphology and a NORMAL Ristocetin response (absent aggregation to ADP, collagen, epinephrine). (4) Heparin-Induced Thrombocytopenia (HIT) (Type II): 5 to 10 days after starting unfractionated or low-molecular-weight heparin, IgG antibodies against Platelet Factor 4 (PF4)–Heparin complexes activate platelets via FcγRIIa receptors, causing a >50% drop in platelet count PLUS paradoxical life-threatening venous and arterial THROMBOSIS (skin necrosis, limb ischemia, PE)—treat by IMMEDIATELY stopping all heparin and starting a Direct Thrombin Inhibitor (Argatroban [hepatically cleared, safe in renal failure] or Bivalirudin)!
Coagulation Profile Master Diagnostic Matrix (Platelets, BT, PT/INR, aPTT, Fibrinogen, D-Dimer)
Every board hematology vignette presenting with spontaneous bleeding or abnormal preoperative labs can be solved systematically by analyzing five core laboratory parameters: Platelet Count (quantitative primary hemostasis), Bleeding Time / Platelet Function Analyzer (qualitative primary hemostasis: vWF-GpIb adhesion and GpIIb/IIIa-fibrinogen aggregation), Prothrombin Time (PT/INR) (extrinsic & common pathway: Factors VII, X, V, II, I—with Factor VII having the shortest half-life [4–6 hours], making PT the first test to rise in early warfarin therapy, vitamin K deficiency, or acute liver failure!), Activated Partial Thromboplastin Time (aPTT) (intrinsic & common pathway: Factors XII, XI, IX, VIII, X, V, II, I), and Fibrinogen / D-dimer (fibrinolysis).
| Coagulation Disorder | Platelet Count | Bleeding Time | PT (INR) | aPTT | Fibrinogen / D-Dimer & Key Pearl |
|---|---|---|---|---|---|
| ITP / Bernard-Soulier / Glanzmann | ↓ (ITP, BSS) or Normal (Glanzmann) | ↑ Prolonged | Normal | Normal | Normal; pure primary hemostasis defect (petechiae, epistaxis) |
| Hemophilia A (VIII) or B (IX) | Normal | Normal | Normal | ↑ Prolonged | Normal; X-linked recessive; hemarthroses; corrects on 1:1 mix |
| von Willebrand Disease (vWD) | Normal | ↑ Prolonged | Normal | ↑ Prolonged (or normal) | Normal; Autosomal dominant; abnormal ristocetin assay; Rx: DDAVP |
| Vitamin K Deficiency / Warfarin | Normal | Normal | ↑↑ Prolonged (1st!) | ↑ Prolonged (late) | Normal fibrinogen; Factors II, VII, IX, X, Protein C/S; neonatal hemorrhage if no IM Vit K |
| Disseminated Intravascular Coagulation (DIC) | ↓ Decreased | ↑ Prolonged | ↑ Prolonged | ↑ Prolonged | ↓ Fibrinogen, ↑↑ D-dimer, ↓ Factor VIII; Schistocytes on smear |
| TTP / HUS | ↓↓ Decreased | ↑ Prolonged | NORMAL! | NORMAL! | Normal Fibrinogen & D-dimer! Schistocytes + elevated LDH |
| Cirrhosis / Liver Failure | ↓ (Splenomegaly / ↓ TPO) | ↑ Prolonged | ↑ Prolonged | ↑ Prolonged | ↓ Factor V & VII, but NORMAL/HIGH Factor VIII (endothelial origin!) |
Hemophilia A (Factor VIII) vs. Hemophilia B (Factor IX) vs. Hemophilia C (Factor XI)
Hemophilia A (Factor VIII deficiency, 80% of cases) and Hemophilia B (Christmas Disease, Factor IX deficiency, 20%) are clinically indistinguishable X-linked recessive disorders affecting male infants and boys (or female carriers with extreme lyonization or Turner syndrome [45,XO]). Because primary platelet plug formation is intact while the intrinsic tenase amplification loop (Factor IXa + Factor VIIIa activating Factor X) is broken, patients present with delayed, deep tissue bleeding: spontaneous recurrent hemarthroses (knee, ankle, elbow joints leading to crippling hemophilic arthropathy), deep intramuscular hematomas (iliopsoas hematoma compressing the femoral nerve!), intracranial hemorrhage, and prolonged re-bleeding hours after dental extraction or circumcision. Laboratory profile shows a prolonged aPTT that CORRECTS on a 1:1 mixing study, with a completely normal Platelet count, normal Bleeding Time, and normal PT/INR. Management of Hemophilia A includes recombinant Factor VIII concentrate, emicizumab (a bispecific monoclonal antibody that bridges Factor IXa and Factor X to mimic Factor VIIIa subcutaneously), or Desmopressin (DDAVP) for MILD Hemophilia A only (plus aminocaproic acid or tranexamic acid for mucosal/dental procedures); Hemophilia B is treated with recombinant Factor IX concentrate (DDAVP has zero effect on Factor IX!). By contrast, Hemophilia C (Factor XI deficiency) is an autosomal recessive disorder (prevalent in Ashkenazi Jewish populations) causing mild surgical/trauma-induced bleeding without spontaneous hemarthroses.
von Willebrand Disease (vWD): Dual Lab Signature, Ristocetin Assay & DDAVP
von Willebrand Disease (vWD) is the most common inherited bleeding disorder overall (affecting ~1% of the population, predominantly autosomal dominant Type 1 quantitative partial deficiency). Synthesized as ultra-large multimers in endothelial Weibel-Palade bodies and megakaryocyte α-granules, von Willebrand Factor (vWF) performs two essential physiological jobs: (1) Primary Hemostasis: vWF binds exposed subendothelial collagen at sites of high shear stress and tethers platelets via the platelet GpIb-IX-V receptor; and (2) Secondary Hemostasis: vWF acts as the protective carrier protein for Factor VIII in plasma, shielding Factor VIII from rapid proteolytic degradation by Activated Protein C. Consequently, vWD presents clinically like a primary platelet disorder—heavy menstrual bleeding (menorrhagia since menarche), recurrent epistaxis, easy bruising, gingival bleeding, and immediate bleeding after tonsillectomy or tooth extraction—yet its laboratory profile uniquely spans BOTH pathways: Prolonged Bleeding Time + Prolonged (or upper-normal) aPTT, with a Normal Platelet count and Normal PT/INR! Diagnosis is confirmed by measuring decreased plasma vWF antigen, decreased Factor VIII activity, and an ABNORMAL Ristocetin Cofactor Assay (ristocetin antibiotic normally induces vWF to bind platelet GpIb and agglutinate platelets in vitro; in vWD, ristocetin-induced platelet agglutination is impaired, but corrects when normal donor plasma is added!). First-line treatment for mild-to-moderate Type 1 vWD is Desmopressin (DDAVP)—a synthetic vasopressin V2 receptor agonist that stimulates endothelial cells to exocytose stored vWF and Factor VIII from Weibel-Palade bodies (note: DDAVP is contraindicated in Type 2B vWD, a gain-of-function mutation where hyper-adhesive vWF multimers cause DDAVP-induced thrombocytopenia; severe Type 3 vWD requires vWF/Factor VIII plasma concentrates).
Vitamin K Deficiency vs. Liver Failure vs. Factor XII (Hageman) Deficiency
Vitamin K is a lipid-soluble cofactor required by hepatic γ-glutamyl carboxylase to carboxylated glutamate residues on Factors II, VII, IX, and X, as well as anticoagulant Proteins C and S (regenerated by Vitamin K epoxide reductase [VKOR], the target of warfarin). Vitamin K deficiency occurs in breastfed newborns who did not receive the mandatory intramuscular Vitamin K1 (phytonadione) injection at birth (sterile neonatal gut lacks vitamin K-synthesizing bacteria and breast milk is low in vitamin K, causing Hemorrhagic Disease of the Newborn: intracranial, umbilical stump, or circumcision bleeding on days 2–7 of life!), as well as in adults on prolonged broad-spectrum antibiotics or with fat malabsorption (celiac, cystic fibrosis, biliary obstruction). Because Factor VII has the shortest half-life, early Vitamin K deficiency prolongs PT/INR first, followed by prolongation of BOTH PT and aPTT (with normal platelets and normal fibrinogen). How do you distinguish Severe Liver Failure from Vitamin K deficiency when both PT and aPTT are prolonged? (1) Parenteral Vitamin K corrects the PT/INR within 24 hours in Vitamin K deficiency, but fails to correct PT in cirrhosis; and (2) Factor VIII is synthesized by vascular endothelial cells (NOT hepatocytes!)—therefore, in cirrhosis, all factors (including Factor V and VII) are low EXCEPT Factor VIII, which is normal or elevated (whereas in DIC, Factor VIII is consumed and low!). Finally, Factor XII (Hageman Factor) deficiency is a classic board trick: it causes a massively prolonged aPTT in vitro (> 100 seconds), yet the patient has ZERO clinical bleeding tendency (and may actually be predisposed to thrombosis due to impaired kallikrein-plasmin activation)!
Microangiopathic Hemolytic Anemias (MAHA): TTP vs. HUS vs. DIC
In Microangiopathic Hemolytic Anemia (MAHA), microvascular platelet-rich or fibrin-rich thrombi form a mechanical meshwork inside arterioles and capillaries that shears passing erythrocytes into helmet cells and triangular fragments (schistocytes), producing intravascular hemolysis (elevated indirect bilirubin, elevated LDH, undetectable haptoglobin, negative Coombs test) and consumptive thrombocytopenia. The crucial board distinction is that TTP and HUS consume ONLY platelets (leaving PT, aPTT, and fibrinogen completely NORMAL), whereas DIC activates the entire coagulation cascade, consuming BOTH platelets AND clotting factors (prolonging PT and aPTT, depleting fibrinogen, and elevating D-dimer)!
| MAHA Syndrome | Primary Pathogenesis | Classic Clinical Presentation | PT / aPTT / Fibrinogen / D-Dimer | Definitive Management & Contraindications |
|---|---|---|---|---|
| TTP (Thrombotic Thrombocytopenic Purpura) | ADAMTS13 deficiency (< 10%) → uncleaved ultra-large vWF multimers trap platelets | Adult female; Pentad (Fever, MAHA, Thrombocytopenia, Renal, Neurologic deficits) | NORMAL PT, NORMAL aPTT, NORMAL Fibrinogen, Normal D-dimer | Emergent Plasmapheresis (PEX) + Steroids + Rituximab/Caplacizumab; NO PLATELETS! |
| Typical HUS (Hemolytic Uremic Syndrome) | EHEC O157:H7 Shiga toxin inactivates 60S ribosome in glomerular endothelium (Gb3) | Child after bloody diarrhea; Triad (MAHA, Thrombocytopenia, Severe AKI; no neuro signs) | NORMAL PT, NORMAL aPTT, NORMAL Fibrinogen, Normal D-dimer | Supportive care ± dialysis; NO antibiotics & NO platelet transfusions! |
| DIC (Disseminated Intravascular Coagulation) | Systemic Tissue Factor activation (Sepsis, Trauma, OB abruption, APL t(15;17)) | Critically ill patient oozing blood from IV lines, gums, Foley + shock / organ failure | ↑↑ PT, ↑↑ aPTT, ↓↓ Fibrinogen (< 100), ↑↑ D-dimer | Treat underlying cause + Cryoprecipitate (for fibrinogen < 100), FFP, and Platelets |
Thrombotic Thrombocytopenic Purpura (TTP): ADAMTS13 Deficiency, Pentad & Plasmapheresis Rule
Thrombotic Thrombocytopenic Purpura (TTP) is caused by severe congenital (Upshaw-Schulman syndrome) or acquired (inhibitory IgG autoantibody, classically in young adult women) deficiency of ADAMTS13 (< 10% activity), the plasma metalloprotease responsible for cleaving ultra-large von Willebrand factor (vWF) multimers as they are secreted from endothelial cells. Without ADAMTS13 cleavage, giant hyper-adhesive vWF multimers remain anchored to microvascular endothelium and spontaneously trap circulating platelets throughout the brain, kidney, and heart—without activating the secondary coagulation cascade. TTP presents with the classic 'FAT RN' Pentad: (1) Fever, (2) Microangiopathic Hemolytic Anemia (MAHA with schistocytes, high LDH, low haptoglobin), (3) Severe Thrombocytopenia (often < 20,000/μL), (4) Renal insufficiency (mild-to-moderate), and (5) Fluctuating Neurologic Deficits (confusion, headache, aphasia, seizures, focal stroke-like symptoms, coma). Note that MAHA + Thrombocytopenia alone in the absence of another cause is sufficient to initiate treatment! Immediate life-saving treatment is emergent Plasma Exchange (Plasmapheresis / PEX) (which removes anti-ADAMTS13 autoantibodies and ultra-large vWF multimers while infusing fresh donor ADAMTS13) plus high-dose glucocorticoids, rituximab, and caplacizumab (an anti-vWF nanobody that blocks vWF-GpIb interaction). CRITICAL BOARD CONTRAINDICATION: NEVER transfuse platelets in a patient with TTP (or HUS)! Infusing exogenous platelets provides fresh 'fuel on the fire,' triggering explosive microvascular thrombosis, cerebral infarction, cardiac arrest, and death!
Hemolytic Uremic Syndrome (HUS): Shiga Toxin (EHEC O157:H7), 60S Ribosome & Antibiotic Trap
Typical Hemolytic Uremic Syndrome (HUS) occurs predominantly in children (< 5–10 years old) 5–10 days after an outbreak of bloody diarrhea (hemorrhagic colitis) transmitted by undercooked ground beef, unpasteurized apple cider/milk, or petting zoos contaminated with Enterohemorrhagic Escherichia coli (EHEC, serotype O157:H7, which fails to ferment sorbitol on MacConkey agar) or Shigella dysenteriae. The bacteria release Shiga toxin (or Shiga-like verotoxin), which enters the bloodstream and preferentially binds to globotriaosylceramide (Gb3) receptors highly expressed on glomerular capillary endothelial cells. Once endocytosed, Shiga toxin cleaves an adenine residue from the 28S rRNA of the 60S ribosomal subunit, halting protein synthesis and causing glomerular endothelial apoptosis, subendothelial swelling, and platelet-fibrin microthrombi. HUS presents with the Classic Triad: (1) MAHA (schistocytes, jaundice, high LDH), (2) Thrombocytopenia, and (3) Severe Acute Kidney Injury (oliguria, uremia, hematuria/proteinuria)—with normal PT/aPTT and absence of the prominent neurologic symptoms or fever seen in TTP. Management of typical EHEC-HUS is strictly supportive (careful IV hydration, electrolyte management, and temporary hemodialysis if uremic); NEVER administer antibiotics (e.g., fluoroquinolones, TMP-SMX) or antimotility agents (loperamide) to a child with suspected EHEC O157:H7 bloody diarrhea, because bacterial lysis triggers massive release of preformed Shiga toxin and dramatically increases the risk of HUS! (By contrast, Atypical HUS lacks a diarrheal prodrome, is caused by unregulated alternative complement pathway activation [Factor H/I mutations], and is treated with eculizumab [anti-C5 monoclonal antibody].)
Disseminated Intravascular Coagulation (DIC): Tissue Factor Triggers ('STOP Making New Thrombi') & Fibrinogen Replacement
Disseminated Intravascular Coagulation (DIC) is an acquired clinicopathologic catastrophe in which systemic exposure of Tissue Factor (Factor III) triggers widespread intravascular activation of the extrinsic coagulation cascade (Factor VIIa), generating diffuse microvascular fibrin thrombi (causing MAHA schistocytes and multiorgan ischemic failure) while simultaneously consuming all endogenous platelets, Fibrinogen, Factors V and VIII, and Antithrombin/Protein C, followed by secondary plasmin-mediated fibrinolysis (generating markedly elevated D-dimer and fibrin split products). The classic board triggers are remembered by the mnemonic 'STOP Making New Thrombi': Sepsis (Gram-negative bacterial lipopolysaccharide endotoxin [Lipid A] inducing monocyte/endothelial Tissue Factor and TNF-α/IL-1), Trauma (especially severe head/brain trauma releasing brain thromboplastin, or extensive burns/rhabdomyolysis), Obstetric complications (amniotic fluid embolism, placental abruption, retained dead fetus, severe preeclampsia/HELLP—placental tissue is rich in Tissue Factor!), Acute Pancreatitis, Malignancy (mucin-producing adenocarcinomas of pancreas/stomach/prostate, and Acute Promyelocytic Leukemia [APL, t(15;17) PML-RARA] where Auer rods release procoagulant tissue factor and annexin II!), Nephrotic syndrome, and Transfusion (ABO-incompatible acute hemolytic transfusion reaction) or Rattlesnake/Viper envenomation. Clinically, patients ooze blood continuously from every IV catheter site, surgical incision, Foley catheter, and endotracheal tube. Treatment requires immediately treating the underlying trigger plus targeted component replacement in bleeding patients: Cryoprecipitate (rich in Fibrinogen, Factor VIII, vWF, Factor XIII) if Fibrinogen is < 100–150 mg/dL, Fresh Frozen Plasma (FFP) to replace clotting factors if PT/aPTT are markedly prolonged, and Platelet transfusion if platelets are < 50,000/μL with active bleeding (or < 10,000–20,000/μL prophylactically).
Quantitative & Qualitative Platelet Disorders: ITP, Bernard-Soulier, Glanzmann & HIT
Isolated thrombocytopenia or mucocutaneous bleeding with normal PT/aPTT localizes the pathology to megakaryocyte production, splenic/autoimmune destruction, or platelet surface glycoprotein receptors (GpIb vs. GpIIb/IIIa).
| Platelet Disorder | Molecular Defect / Antibody | Platelet Count & Morphology | Ristocetin Assay | First-Line Therapy & Critical Pearls |
|---|---|---|---|---|
| Immune Thrombocytopenia (ITP) | IgG autoantibodies vs. GpIIb/IIIa → splenic macrophage Fc phagocytosis | ↓↓ Platelets; normal RBCs/WBCs; ↑ megakaryocytes on bone marrow | Normal | Child (skin only): Observe; Adult (< 30k/bleeding): Steroids ± IVIG / Anti-D; 2nd-line: TPO-RA, Rituximab, Splenectomy |
| Bernard-Soulier Syndrome | AR deficiency of GpIb receptor (impaired vWF adhesion) | Mild ↓ platelets with GIANT PLATELETS ('Big Suckers') | ABNORMAL (does NOT correct with normal plasma!) | Platelet transfusions, antifibrinolytics (tranexamic acid), DDAVP during bleeding |
| Glanzmann Thrombasthenia | AR deficiency of GpIIb/IIIa receptor (impaired fibrinogen aggregation) | Normal count, normal size, no platelet clumping on smear | NORMAL (impaired ADP/collagen aggregation) | Platelet transfusions (HLA-matched), recombinant Factor VIIa, antifibrinolytics |
| Heparin-Induced Thrombocytopenia (HIT) | IgG vs. Heparin-PF4 complex → FcγRIIa platelet activation | > 50% platelet drop 5–10 days after heparin + THROMBOSIS | Confirm with PF4 ELISA + Serotonin Release Assay (SRA) | Stop ALL heparin + Start Argatroban or Bivalirudin; NO warfarin until platelets > 150k! |
| Uremic Platelet Dysfunction | Uremic toxins (guanidinosuccinic acid / NO) impair GpIIb/IIIa activation | NORMAL platelet count, normal PT/aPTT, ↑ Bleeding Time | Impaired adhesion/aggregation | Desmopressin (DDAVP) + intensive hemodialysis |
Immune Thrombocytopenia (ITP): Anti-GpIIb/IIIa IgG, Pediatric vs. Adult Course & Therapy
Immune Thrombocytopenia (ITP) is an acquired autoimmune disorder caused by IgG autoantibodies directed against platelet surface glycoproteins—most commonly GpIIb/IIIa (or GpIb-IX). IgG-coated platelets are opsonized and prematurely phagocytosed by splenic macrophages via Fcγ receptors (and anti-GpIIb/IIIa antibodies also impair bone marrow megakaryocyte maturation). ITP is a diagnosis of exclusion characterized by isolated thrombocytopenia (< 100,000/μL) with a completely normal WBC count, normal hemoglobin/RBC morphology (no schistocytes!), normal PT/aPTT, and absence of splenomegaly (if bone marrow biopsy is performed, it shows increased numbers of large megakaryocytes). Always screen adults with new ITP for HIV and Hepatitis C virus (HCV), as well as SLE, CLL, and H. pylori! Clinically, ITP bifurcates by age: (1) Pediatric Acute ITP typically occurs in a child aged 2–6 years 1–3 weeks after a viral URI or viral exanthem, presenting with sudden-onset diffuse petechiae, purpura, or epistaxis; 80% of children recover spontaneously within 2–6 months—therefore, if the child has only cutaneous symptoms (petechiae/bruising) without active mucosal hemorrhage, management is OBSERVATION ALONE regardless of how low the platelet count is! (2) Adult Chronic ITP typically affects women of childbearing age insidiously and rarely remits spontaneously. In adults, if platelets are ≥ 30,000/μL with no bleeding, observe; if platelets are < 30,000/μL or active bleeding is present, first-line therapy is corticosteroids (prednisone or high-dose dexamethasone), adding IVIG or anti-D (Rho[D]) immune globulin (which competitively saturates splenic macrophage Fc receptors; anti-D only works in Rh-positive, non-splenectomized patients!) when rapid platelet elevation is required for life-threatening bleeding. Second-line options for steroid-refractory chronic ITP are TPO receptor agonists (romiplostim, eltrombopag), rituximab, or splenectomy.
Bernard-Soulier Syndrome (GpIb Adhesion) vs. Glanzmann Thrombasthenia (GpIIb/IIIa Aggregation) & Uremic Platelets
Two autosomal recessive qualitative platelet receptor disorders are classic board foils: (1) Bernard-Soulier Syndrome ('Big Suckers') is caused by a congenital deficiency of the platelet GpIb-IX-V receptor complex, which mediates platelet ADHESION to subendothelial von Willebrand Factor (vWF). Laboratory findings show prolonged bleeding time, mild-to-moderate thrombocytopenia with pathognomonic GIANT PLATELETS on peripheral blood smear, and an abnormal Ristocetin Cofactor Assay that DOES NOT CORRECT when normal donor plasma (containing vWF) is added (because the patient's own platelets lack GpIb receptors!). (2) Glanzmann Thrombasthenia is caused by a congenital deficiency of the platelet GpIIb/IIIa (αIIbβ3 integrin) receptor, which binds fibrinogen to cross-link adjacent platelets during platelet AGGREGATION. Laboratory findings show prolonged bleeding time, NORMAL platelet count, NORMAL platelet size (though blood smear shows absence of normal platelet clumping), and a NORMAL Ristocetin assay, with absent aggregation in response to ADP, collagen, epinephrine, or arachidonic acid. (3) Uremic Platelet Dysfunction: In advanced CKD/uremia, accumulated guanidinosuccinic acid and nitric oxide impair platelet GpIIb/IIIa activation and adhesion, causing mucocutaneous bleeding with a prolonged bleeding time despite a normal platelet count and normal PT/aPTT; acute treatment before surgery or during bleeding is Desmopressin (DDAVP) + intensive hemodialysis.
Heparin-Induced Thrombocytopenia (HIT): PF4 IgG, 4T Score & Direct Thrombin Inhibitors
Type II Heparin-Induced Thrombocytopenia (HIT) is a life- and limb-threatening PROTHROMBOTIC drug reaction occurring 5–10 days after starting unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) (or within < 24 hours if the patient was exposed to heparin within the prior 100 days and harbors preformed antibodies). Pathogenesis is driven by IgG autoantibodies directed against complexes of Heparin bound to Platelet Factor 4 (PF4) (a positively charged cytokine released from platelet α-granules). The Fc tails of these IgG-PF4-heparin immune complexes cross-link FcγRIIa receptors on the surface of neighboring platelets, triggering intense intravascular platelet activation, release of procoagulant microparticles, and explosive arterial and venous THROMBOSIS (deep vein thrombosis, pulmonary embolism, limb ischemia/gangrene, mesenteric ischemia, stroke, and bilateral adrenal vein thrombosis/hemorrhage), while splenic macrophages clear coated platelets, causing a > 50% drop in platelet count from baseline (typically nadir 20,000–100,000/μL). Pre-test probability is calculated using the 4T Score (degree of Thrombocytopenia, Timing of onset [5–10 days], Thrombosis/skin necrosis, and absence of oTher causes) and confirmed via anti-PF4-heparin ELISA followed by the gold-standard Serotonin Release Assay (SRA). IMMEDIATE MANAGEMENT WHEN HIT IS SUSPECTED: (1) Immediately discontinue ALL forms of heparin (including LMWH/enoxaparin, heparin-coated central lines, and heparin IV flushes!); (2) Immediately initiate a non-heparin anticoagulant—specifically a parenteral Direct Thrombin Inhibitor (Argatroban [hepatically cleared—preferred in renal failure!] or Bivalirudin), Fondaparinux, or a DOAC (Apixaban/Rivaroxaban), even if no thrombosis is clinically evident yet; and (3) NEVER start Warfarin until the platelet count has fully recovered (> 150,000/μL) while bridged on a direct thrombin inhibitor, because warfarin acutely depletes Protein C and precipitates warfarin-induced skin necrosis and venous limb gangrene!
Inherited Thrombophilias, 1:1 Plasma Mixing Studies & Anticoagulant Reversal
When a young patient (< 45 years old) presents with an unprovoked deep vein thrombosis (DVT), pulmonary embolism (PE), recurrent pregnancy loss, or thrombosis in an unusual venous bed (cerebral, portal, hepatic, or mesenteric veins), the diagnostic workup targets inherited and acquired hypercoagulable states and interprets 1:1 plasma mixing studies.
| Thrombophilia / Inhibitor / Drug | Molecular Mechanism | Classic Board Vignette Clue | Diagnostic Test / Monitoring | Specific Management / Reversal |
|---|---|---|---|---|
| Factor V Leiden (#1 Inherited) | Arg506Gln point mutation → Factor Va resistant to Activated Protein C (APC) cleavage | Young Caucasian patient with unprovoked DVT/PE or cerebral/mesenteric vein thrombosis | APC resistance assay + F5 Arg506Gln PCR | Direct oral anticoagulant (Apixaban, Rivaroxaban) or Warfarin |
| Prothrombin G20210A (#2 Inherited) | 3'-UTR point mutation → ↑ Prothrombin (Factor II) synthesis | Unprovoked DVT/PE with normal APC resistance | Prothrombin G20210A DNA PCR (↑ plasma prothrombin level) | DOAC or Warfarin |
| Protein C or S Deficiency | Deficient inactivation of Factors Va and VIIIa (short half-life Vitamin K factors) | Warfarin-induced skin necrosis (painful black eschars on breast/thigh 3 days after starting warfarin without heparin) | Functional Protein C/S assay (check off warfarin!) | Stop warfarin → give Vitamin K + Heparin + Protein C concentrate/FFP; always bridge with heparin! |
| Antithrombin Deficiency | Deficient inhibition of Factors IIa and Xa (inherited AD or lost in Nephrotic Syndrome urine) | DVT/renal vein thrombosis + Heparin resistance (aPTT fails to increase despite high-dose IV UFH!) | Decreased Antithrombin activity assay | Antithrombin concentrate or switch to Argatroban / Direct Xa inhibitor |
| Antiphospholipid Syndrome (Lupus Anticoagulant) | Antiphospholipid antibodies (Lupus anticoagulant, anti-cardiolipin, anti-β2-GPI) | SLE female with DVT/stroke + recurrent miscarriages + prolonged aPTT that FAILS to correct on 1:1 mix + false+ VDRL | 1:1 mix fails to correct; confirmed by dRVVT (repeat at 12 weeks) | Lifelong Warfarin (DOACs inferior); LMWH + low-dose Aspirin during pregnancy |
Interactive 2K Master Atlas Plate
1:1 Plasma Mixing Study Algorithm: Factor Deficiency vs. Lupus Anticoagulant vs. Acquired Factor VIII Inhibitor
When a patient has an isolated prolonged aPTT with a normal PT/INR, the immediate next diagnostic step is a 1:1 Plasma Mixing Study, in which the patient's plasma is mixed 1:1 with pooled normal donor plasma (which supplies 50% of every clotting factor—more than enough to normalize the aPTT if a factor is simply missing): (1) aPTT CORRECTS into the normal range: The patient has an intrinsic pathway Clotting Factor Deficiency—either Hemophilia A (Factor VIII), Hemophilia B (Factor IX), Hemophilia C (Factor XI), or von Willebrand Disease (or non-bleeding Factor XII deficiency). (2) aPTT FAILS TO CORRECT (remains prolonged): The patient's plasma contains a circulating INHIBITOR (autoantibody) that neutralizes the donor plasma! You must immediately distinguish the two classic inhibitors by their clinical presentation: If the patient presents with recurrent venous/arterial THROMBOSIS or recurrent 2nd/3rd-trimester miscarriages (often in a young woman with SLE), the culprit is the Lupus Anticoagulant (Antiphospholipid Syndrome)—an antiphospholipid antibody (alongside anti-cardiolipin and anti-β2-glycoprotein-I antibodies) that binds the artificial phospholipid reagent in the lab tube to falsely prolong the aPTT in vitro (and cause a false-positive RPR/VDRL syphilis test), while activating endothelium and platelets to cause hypercoagulable thrombosis in vivo (confirmed via the Dilute Russell Viper Venom Time [dRVVT]; treat with lifelong Warfarin, or LMWH + low-dose Aspirin during pregnancy!). Conversely, if an elderly patient, postpartum woman, or patient with rheumatoid arthritis/malignancy presents with massive spontaneous subcutaneous ecchymoses, retroperitoneal hematomas, or muscle bleeding and a non-correcting prolonged aPTT, the culprit is an Acquired Factor VIII Inhibitor (Acquired Hemophilia A)!
Inherited Thrombophilias: Factor V Leiden, Prothrombin G20210A, Protein C/S & Antithrombin Deficiency
Four major inherited thrombophilias predispose to venous thromboembolism (DVT/PE): (1) Factor V Leiden (#1 most common inherited thrombophilia in Caucasians, 5% prevalence): An autosomal dominant missense point mutation (Arg506Gln) in the F5 gene eliminates the specific cleavage site on Factor Va recognized by Activated Protein C (APC). Consequently, Factor Va remains constitutively active ('APC resistance'), driving unchecked prothrombinase complex thrombin generation (Note: because the mutant Factor V protein is already resistant to APC, adding exogenous Protein C will NOT correct the defect!). (2) Prothrombin Gene Mutation (G20210A, #2 most common): A point mutation in the 3' untranslated region (3'-UTR) of the prothrombin (F2) gene increases mRNA stability and elevates plasma prothrombin (Factor II) levels 30% above normal. (3) Protein C or Protein S Deficiency: Vitamin K-dependent endogenous anticoagulants synthesized by the liver that proteolytically inactivate Factors Va and VIIIa. Because Protein C has a short half-life (6–8 hours, comparable to Factor VII) compared to Prothrombin (Factor II, 60 hours) and Factor X (40 hours), initiating Warfarin without a heparin bridge in a patient with heterozygous Protein C or S deficiency causes Protein C levels to plummet before Factors II and X fall, creating a transient paradoxical hypercoagulable state within 2–5 days that causes painful dermal microvascular thrombosis and black eschars over adipose-rich areas (Warfarin-Induced Skin Necrosis over breasts, buttocks, and thighs; treat by stopping warfarin, giving Vitamin K + FFP/Protein C concentrate + Heparin!). (4) Antithrombin (ATIII) Deficiency: Antithrombin normally inhibits Factor IIa (thrombin) and Factor Xa (and Factors IXa, XIa, XIIa). Acquired deficiency occurs in Nephrotic Syndrome (urinary loss of antithrombin in massive proteinuria, predisposing to renal vein thrombosis!). Because Unfractionated Heparin (UFH) works by binding Antithrombin and accelerating its activity 1,000-fold, a patient with Antithrombin deficiency exhibits heparin resistance: escalating doses of IV heparin fail to prolong the aPTT (treat with Antithrombin concentrate or a direct thrombin/Xa inhibitor that does not require antithrombin!).
Anticoagulant Mechanisms, Monitoring & Emergency Reversal Agents
Board exams heavily test emergency reversal of anticoagulants during life-threatening hemorrhage (e.g., intracranial hemorrhage or massive GI bleed): (1) Unfractionated Heparin (UFH) (potentiates Antithrombin against IIa and Xa; monitored by aPTT; safe in severe renal failure): reverse immediately with Protamine Sulfate (a positively charged arginine-rich peptide that binds negatively charged heparin). (2) Low-Molecular-Weight Heparin (Enoxaparin) (potentiates Antithrombin predominantly against Factor Xa; renally cleared): partially (~60%) reversed by Protamine Sulfate (or Andexanet alfa). (3) Warfarin (inhibits VKOR; monitored by PT/INR; metabolized by CYP2C9): for life-threatening bleeding, reverse immediately with 4-Factor Prothrombin Complex Concentrate (4F-PCC, containing Factors II, VII, IX, X + Proteins C/S) PLUS slow IV Vitamin K1 (or FFP if PCC is unavailable). (4) Direct Thrombin Inhibitor — Dabigatran (oral): reverse immediately with Idarucizumab (humanized monoclonal antibody fragment that binds dabigatran) or hemodialysis. (5) Direct Factor Xa Inhibitors — Apixaban, Rivaroxaban, Edoxaban ('-xabans'): reverse with Andexanet alfa (a recombinant catalytically inactive Factor Xa decoy protein that sequesters Xa inhibitors) or 4-Factor PCC. (6) Fibrinolytics — Alteplase (tPA): reverse life-threatening post-tPA hemorrhage with Cryoprecipitate + Aminocaproic acid or Tranexamic acid (competitive inhibitors of plasminogen activation).
Transfusion Medicine, Acute Blood Product Reactions & Anticoagulant Reversal Protocols
Rapid differentiation of acute transfusion reactions and evidence-based reversal of life-threatening anticoagulant-associated hemorrhage are critical high-yield competencies across Internal Medicine, Surgery, Emergency Medicine, and OB/GYN shelf and board examinations.
| Transfusion Reaction | Onset & Clinical Presentation | Immunologic Mechanism & Donor/Recipient Factor | Immediate Management & Prevention Strategy |
|---|---|---|---|
| Acute Hemolytic Transfusion Reaction (AHTR) | Within minutes to 1 hour: fever, chills, flank/back pain, hemoglobinuria, hypotension, DIC/oozing from IV sites | Type II hypersensitivity: recipient preformed IgM/IgG anti-A or anti-B antibodies lyse ABO-incompatible donor RBCs (clerical error #1 cause) | STOP transfusion immediately; aggressive IV 0.9% NaCl + furosemide to maintain urine output; positive Direct Coombs test |
| Febrile Non-Hemolytic Transfusion Reaction (FNHTR) | 1 to 6 hours: isolated fever (rise >= 1 deg C) and rigors without hemolysis or hypotension | Cytokines (IL-1, IL-6, TNF-alpha) accumulated from donor leukocytes during storage, or recipient anti-HLA antibodies | Stop/pause transfusion to rule out AHTR; give acetaminophen; prevent future episodes with pre-storage leukoreduced blood products |
| Transfusion-Related Acute Lung Injury (TRALI) | Within 6 hours: acute hypoxemic respiratory distress, bilateral pulmonary infiltrates, non-cardiogenic pulmonary edema (normal JVP/BNP, hypotension) | Donor anti-HLA or anti-HNA (human neutrophil antigen) antibodies (often from multiparous female donors) activate recipient pulmonary neutrophils | Stop transfusion; supportive ICU respiratory care (supplemental O2 / low-tidal-volume mechanical ventilation); do NOT give diuretics |
| Transfusion-Associated Circulatory Overload (TACO) | Within 6 hours: dyspnea, orthopnea, hypertension, tachycardia, elevated JVP, S3 gallop, markedly elevated BNP | Hydrostatic volume overload from rapid infusion rate or excessive blood product volume in patients with CHF or renal impairment | Stop transfusion; sit patient upright, administer intravenous loop diuretics (furosemide) and supplemental oxygen; prevent via slower infusion |
| Anaphylactic Transfusion Reaction | Within seconds to minutes (after a few mL): angioedema, bronchospasm/wheezing, stridor, hypotension, shock without fever | Type I IgE-mediated hypersensitivity in a patient with Selective IgA Deficiency who has preformed anti-IgA antibodies against donor plasma IgA | Stop transfusion; immediate IM/IV epinephrine, airway protection, fluids; prevent with washed RBCs or IgA-deficient donor plasma |
Differentiating TRALI vs. TACO at the Bedside
The single highest-yield transfusion medicine discriminator on board exams contrasts TRALI (non-cardiogenic inflammatory permeability edema) with TACO (cardiogenic hydrostatic volume overload), both presenting with acute hypoxemia and bilateral chest radiograph infiltrates within 6 hours of transfusion. TRALI is driven by donor anti-leukocyte antibodies triggering neutrophil sequestration and capillary leak in the pulmonary microvasculature, presenting with normal jugular venous pressure, normal PCWP (<18 mmHg), normal BNP, fever, and hypotension; diuretics are contraindicated because the patient is intravascularly depleted. Conversely, TACO results from hydrostatic fluid overload, presenting with hypertension, jugular venous distension, an S3 gallop, pulmonary rales, and a markedly elevated BNP, responding rapidly to intravenous loop diuresis (furosemide).
Emergency Reversal of Warfarin, Heparin, Factor Xa Inhibitors & Dabigatran
For life-threatening hemorrhage (such as intracranial hemorrhage or massive GI bleed) on warfarin, administer 4-factor Prothrombin Complex Concentrate (4F-PCC, containing Factors II, VII, IX, X and Proteins C and S) PLUS intravenous Vitamin K1 (phytonadione 10 mg slow IV); 4F-PCC normalizes the INR within 15 minutes without the volume overload risk of fresh frozen plasma (FFP), while IV vitamin K sustains hepatic gamma-carboxylation after PCC factors decay. Unfractionated heparin is reversed immediately by protamine sulfate (positively charged arginine-rich peptide that binds negatively charged heparin), direct Factor Xa inhibitors (apixaban, rivaroxaban) are reversed by andexanet alfa (recombinant decoy Factor Xa) or 4F-PCC, and the direct thrombin inhibitor dabigatran is reversed by the humanized monoclonal antibody fragment idarucizumab.
COMLEX / OMM Integration
NBOME High-Yield Correlate
Spleen & Liver Viscerosomatics, Chapman Points, Hemophilic Arthropathy & OMT Contraindications
- Absolute & Relative OMT Contraindications in Bleeding & Thrombosis: Osteopathic board examinations rigorously test safety contraindications in hematologic disorders: (1) Acute Deep Vein Thrombosis (DVT): Any direct myofascial, effleurage, or pedal/thoracic lymphatic pump technique over or distal to an acute DVT is STRICTLY CONTRAINDICATED due to the fatal risk of dislodging the thrombus and precipitating a massive pulmonary embolism! (2) Severe Thrombocytopenia (ITP, TTP, DIC with platelets < 20,000–50,000/μL), Hemophilia A/B, or Therapeutic Anticoagulation (Supratherapeutic INR): High-Velocity Low-Amplitude (HVLA) thrust techniques and vigorous deep soft-tissue/myofascial techniques are strictly contraindicated due to the risk of epidural/spinal hematoma, vertebral artery dissection, or intramuscular hemorrhage. Gentle indirect techniques (Counterstrain, Balanced Ligamentous Tension [BLT], and gentle cranial/functional release) are the only safe modalities once acute bleeding is controlled.
- Iliopsoas Hematoma in Hemophilia A/B: Spontaneous retroperitoneal hemorrhage into the iliopsoas muscle sheath is a classic complication of Hemophilia A/B or over-anticoagulation. It presents with acute groin/flank pain, severe hip flexion contracture (positive psoas sign / L1–L2 flexion somatic dysfunction), and ipsilateral FEMORAL NERVE (L2–L4) compression (weakness of quadriceps knee extension, loss of patellar reflex, and numbness over the anterior thigh and medial leg [saphenous nerve]). Always transfuse Factor VIII/IX and obtain a CT scan—never perform psoas muscle energy or deep psoas counterstrain inhibition on an acute iliopsoas hematoma!
- Splenic & Hepatic Autonomics & Chapman Points: The spleen (site of platelet destruction in ITP) receives sympathetic outflow from T6–T10 (left-sided) via the greater splanchnic nerve and celiac ganglion, with its anterior Chapman point at the left 7th intercostal space (posterior: left T7–T8). Note also that splenic massage / thoracic pump is contraindicated in acute infectious mononucleosis or severe splenomegaly due to splenic rupture risk.
Board Traps & Common Distractors
- Platelet Transfusion Contraindication in TTP and HUS: Never transfuse platelets into a patient with suspected Thrombotic Thrombocytopenic Purpura (TTP) or Hemolytic Uremic Syndrome (HUS)! Infusing platelets into plasma rich in uncleaved ultra-large vWF multimers fuels explosive microvascular thrombosis, stroke, myocardial infarction, and death; initiate emergent Plasmapheresis (PEX) immediately for TTP.
- Antibiotic Contraindication in EHEC O157:H7 Bloody Diarrhea: Never prescribe antibiotics (fluoroquinolones, TMP-SMX) or antimotility agents to a child presenting with bloody diarrhea from suspected Enterohemorrhagic E. coli (O157:H7); bactericidal lysis releases massive quantities of preformed Shiga toxin, precipitating Hemolytic Uremic Syndrome (HUS).
- Warfarin Monotherapy Trap in Heparin-Induced Thrombocytopenia (HIT): In a patient with HIT (> 50% platelet drop 5–10 days after heparin exposure), immediately stop all heparin (including LMWH and line flushes) and start a parenteral Direct Thrombin Inhibitor (Argatroban or Bivalirudin); never initiate Warfarin until the platelet count has recovered above 150,000/μL, or acute Protein C depletion will cause venous limb gangrene and warfarin skin necrosis.
- Heparin Resistance in Antithrombin Deficiency / Nephrotic Syndrome: If a patient with a massive DVT or pulmonary embolism receives escalating doses of intravenous Unfractionated Heparin (UFH) without any prolongation of the aPTT, suspect Antithrombin (ATIII) deficiency (either congenital or acquired from urinary loss in Nephrotic Syndrome); administer Antithrombin concentrate or switch to a Direct Thrombin/Factor Xa inhibitor.
- Prolonged aPTT that Fails to Correct on 1:1 Mixing Study: Do not assume a prolonged aPTT always indicates a bleeding disorder! If a 1:1 mixing study fails to correct the aPTT in a patient with DVT, stroke, or recurrent miscarriages, the diagnosis is Lupus Anticoagulant (Antiphospholipid Syndrome)—a severe prothrombotic state requiring lifelong anticoagulation.
- Pediatric Acute Post-Viral ITP Observation Rule: In a young child presenting with isolated petechiae and purpura (no active mucosal or intracranial bleeding) 2 weeks after a viral illness and a platelet count of 15,000/μL (with normal WBC and Hgb), the correct management is reassurance and observation alone (do NOT perform a bone marrow biopsy or splenectomy).
Previous Chapter
•
Vol 2: Clinical Ch. 34
Cognitive Decline
Vol 2: Clinical Ch. 36
•
Next Chapter
HIV Medicine, Opportunistic Infections & Antiretroviral Therapy
Table of Contents (105 Chapters)
Volume 2: Organ System Clinical Pathology • Chapter 35 of 60